Ribomic

Ribomic R&D per Employee

The R&D Spending per Employee of Ribomic (4591.T) as of Oct 30, 2026 is 32.16 M JPY. In the previous year, R&D Spending per Employee was 26.68 M JPY — a change of 20.54% (higher).

R&D per Employee

32.16 MJPY

YoY

20.54%

Last updated:

R&D Spending per Employee of Ribomic is 2026 32.16 M JPY. R&D Spending per Employee of Ribomic was 2025 26.68 M JPY. It decreases by 20.54% higher compared to the previous year.

The Ribomic R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2019
23.51 M JPY
Jan 1, 2020
26.30 M JPY
Jan 1, 2021
37.28 M JPY
Jan 1, 2022
58.70 M JPY
Jan 1, 2023
59.63 M JPY
Jan 1, 2024
30.16 M JPY
Jan 1, 2025
26.68 M JPY
Jan 1, 2026
32.16 M JPY
The Ribomic R&D per Employee history
YEARR&D per EmployeeYoY
32.16 MJPY+20.54%
26.68 MJPY-11.53%
30.16 MJPY-49.43%
59.63 MJPY+1.59%
58.70 MJPY+57.44%
37.28 MJPY+41.75%
26.30 MJPY+11.88%
23.51 MJPY-11.24%
26.48 MJPY+14.92%
23.05 MJPY+36.61%
16.87 MJPY+58.91%
10.62 MJPY-34.88%
16.30 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

R&D Spending per Employee of Ribomic is 32.16 M JPY in 2026.

R&D Spending per Employee of Ribomic changed from 26.68 M JPY to 32.16 M JPY, representing a 20.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Ribomic since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Ribomic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Ribomic

All Key Metrics — Ribomic